Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977586 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3AKR1C3 | |
| SCHEMBL1977584 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3AKR1C3 | |
| SCHEMBL20037561 | 0.85 | HRH3 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL1751868 | 0.80 | USP30 (0.36) | AKR1C3HRH3 | |
| SCHEMBL1751867 | 0.80 | USP30 (0.36) | AKR1C3HRH3 | |
| SCHEMBL25243349 | 0.80 | MAPT (0.38) | HRH3 | |
| SCHEMBL25243350 | 0.80 | MAPT (0.38) | HRH3 | |
| SCHEMBL1978384 | 0.80 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1978385 | 0.80 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14845639 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | CDK4, CDKL4, CDK2 | CHRNB2 4767/4885CHRNA4 4362/4885CHRNB4 4697/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | CHRNB2 4767/4885CHRNA4 4362/4885CHRNB4 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.